Expression of smad7 in cholangiocarcinoma: Prognostic significance and implications for tumor metastasis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5161-5165

  Huang, Qiang ^a,b   Liu, Lei ^a   Liu, Chen Hai ^a   Shao, Feng ^a   Xie, Fang ^a   Zhang, Chuan Hai ^a   Hu, San Yuan ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Epithelial mesenchymal transition; Metastasis; Prognostic indicator; Smad7

Indexed keywords

EID: 84874004118     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5161     Document Type: Article

References (31)

1. Aljiffry M, Walsh M J, Molinari M (2009). Advance in diagnosis, treatment and palliation of cholangiocarcarcinoma: 1990-2009. World J Gastrointestinal, 15, 4240-62.
2. Chen YK, Huang AH, Cheng PH, et a1(2012). Overexpression of Smad proteins, especially Smad7, in oral epithelial dysplasias. Clin Oral Investig, 6, 6.
3. Dahler AL, Cavanagh LL, Saunders NA (2001). Suppression of keratinocyte growth and differentiation by transforming growth factor beta1 involves multiple signaling pathways. J Invest Dermatol, 116, 266-74.
4. Drabsch Y, Ten Dijke P (2012). TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev, 7, 20.
5. Gratchev A, Kzhyshkowska J, Kannookadan S, et al (2008).Activation of a TGF-beta-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-beta receptor II. J Immunol, 180, 6553-65.
6. Halder SK, Rachakonda G, Deane NG, et al (2008). Smad7 induces hepatic metastasis in colorectal cancer. Brit J Cancer, 4, 957-65.
7. Hayashi H, Abollah S, Qiu Y, et al (1997). The MAD-related protein Smad7 associates with the TGF-beta receptor and functions as an antagonist of TGF-beta signaling. Cell, 89, 1165-73.
8. Iiizumi M, Liu W, Pai SK, et al (2008). Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta, 1786, 87-104.
9. Iwatsuki M, Mimori K, Yokobori T, et al (2010). Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci, 101, 293-9.
10. Kalluri R, Weinberg RA(2009). The basics of epithelial-mesenchymal transition. J Clin Invest, 119, 1420-8.
11. Kim YH, Lee HS, Lee HJ, et al (2004). Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol, 15, 574-80.
12. Kleeff J, Ishiwata T, Maruyama H, et al(1999). The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 18, 5363-72.
13. Kokkinos MA, Wafai R, Wong MK, et al (2007). Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tiss Organs, 185, 191-203.
14. Lan HY, Chung AC (2011). Transforming growth factor-β and Smads. Contrib Nephrol, 170, 75-82.
15. Leng A, Liu T, He Y, Li Q, Zhang G (2009). Smad4/Smad7 balance: A role of tumorigenesis in gastric cancer. Exp Mol Pathol, 87, 48-53.
16. Li H, Qin Y, Cui Y, et al (2011). Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg, 28, 226-31.
17. Li Y, Wang JP, Santen RJ, et al (2010). Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology, 151, 5146-56.
18. Liu Q, Zhang Y, Mao H, et al (2012). A crosstalk between the Smad and JNK signaling in the TGF-β-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. PLoS One, 7, e32009.
19. Moustakas A, Heldin CH (2007). Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci, 98, 1512-20.
20. Nakajima S, Doi R, Toyoda E, et al (2004). N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res, l0, 4125-33.
21. Neilson EG (2006). Mechanisms of disease: Fibroblasts-a new look at an old problem. Nat Clin Pract Nephrol, 2, 101-8.
22. Park YN, Chae KJ, Oh B K, et al (2004). Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism transforming growth factor-beta. Hepatogastroenterology, 51, 396-400.
23. Peinado H, Olmeda D, Cano A (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer, 7, 415-28.
24. Pittman AM, Naranjo S, Webb E, et al(2009). The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res, 19, 987-93.
25. Polette M, Mestdagt M, Bindels S, et al (2007). Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes[J].Cells Tiss Organs, 185, 61-5.
26. Sabe H (2011). Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor β signalling. J Biochem, 149, 633-9.
27. Sandusky G, Berg DT, Richardson MA, et al (2002). Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads[J]. J Biol Chem, 277, 49815-9.
28. Sethi S, Sarkar FH, Ahmed Q, et al (2011). Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol, 4, 222-6.
29. Yu H, Zhao G, Li H, et al (2012). Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. Gene, 1, 3.
30. Zhu HJ, Iaria J, Sizeland AM(1999). Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J Biol Chem, 274, 32258-64.
31. Zhu L, Wang L, Wang X, et al (2011). Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS One, 6, e17415.